Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | IDO1 | P14902 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 4/20 | 0.33 |
| ▸ | HPGD | P15428 | 2/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | BCHE | P06276 | 3/20 | 0.32 |
| ▸ | GSTP1 | P09211 | 2/20 | 0.32 |
| ▸ | ELANE | P08246 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17356766 | 1.00 | KMT2A (0.38) | KMT2AMEN1ALDH1A1IDO1HTT | |
| SCHEMBL25967804 | 0.90 | MEN1 (0.35) | KMT2AMEN1ALDH1A1IDO1GSTP1 | |
| SCHEMBL25911629 | 0.88 | KMT2A (0.37) | KMT2AMEN1ALDH1A1IDO1HTT | |
| SCHEMBL20484797 | 0.88 | KMT2A (0.37) | KMT2AMEN1ALDH1A1IDO1HTT | |
| SCHEMBL1059333 | 0.88 | KMT2A (0.37) | KMT2AMEN1ALDH1A1IDO1HTT | |
| SCHEMBL21085574 | 0.88 | KMT2A (0.37) | KMT2AMEN1ALDH1A1IDO1HTT | |
| SCHEMBL2720695 | 0.84 | KMT2A (0.37) | KMT2AMEN1ALDH1A1IDO1HTT | |
| SCHEMBL12306538 | 0.83 | MEN1 (0.34) | KMT2AMEN1ALDH1A1IDO1BCHE | |
| SCHEMBL2719573 | 0.83 | MEN1 (0.34) | KMT2AMEN1ALDH1A1IDO1BCHE | |
| SCHEMBL2717735 | 0.83 | MEN1 (0.34) | KMT2AMEN1ALDH1A1IDO1BCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230257413-A1 | ARTIFICIAL NUCLEIC ACID, METHOD FOR PRODUCING SAME, AND USE THEREOF | RIKEN GENESIS CO., LTD. (JP) | 2023-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230257413-A1 | ARTIFICIAL NUCLEIC ACID, METHOD FOR PRODUCING SAME, AND USE THEREOF | NSUN2, NSUN3, POLRMT | KMT2A 229/4885MEN1 933/4885ALDH1A1 986/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.